全文获取类型
收费全文 | 621篇 |
免费 | 28篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 31篇 |
妇产科学 | 6篇 |
基础医学 | 45篇 |
口腔科学 | 7篇 |
临床医学 | 56篇 |
内科学 | 196篇 |
皮肤病学 | 16篇 |
神经病学 | 76篇 |
特种医学 | 64篇 |
外科学 | 25篇 |
综合类 | 19篇 |
预防医学 | 22篇 |
眼科学 | 4篇 |
药学 | 82篇 |
肿瘤学 | 18篇 |
出版年
2022年 | 1篇 |
2021年 | 2篇 |
2020年 | 2篇 |
2019年 | 2篇 |
2018年 | 5篇 |
2017年 | 3篇 |
2016年 | 2篇 |
2015年 | 5篇 |
2014年 | 6篇 |
2013年 | 13篇 |
2012年 | 13篇 |
2011年 | 10篇 |
2010年 | 13篇 |
2009年 | 18篇 |
2008年 | 18篇 |
2007年 | 23篇 |
2006年 | 14篇 |
2005年 | 13篇 |
2004年 | 11篇 |
2003年 | 14篇 |
2002年 | 17篇 |
2001年 | 25篇 |
2000年 | 18篇 |
1999年 | 21篇 |
1998年 | 14篇 |
1997年 | 14篇 |
1996年 | 21篇 |
1995年 | 12篇 |
1994年 | 22篇 |
1993年 | 13篇 |
1992年 | 18篇 |
1991年 | 22篇 |
1990年 | 19篇 |
1989年 | 26篇 |
1988年 | 28篇 |
1987年 | 23篇 |
1986年 | 31篇 |
1985年 | 25篇 |
1984年 | 28篇 |
1983年 | 16篇 |
1982年 | 15篇 |
1981年 | 14篇 |
1980年 | 12篇 |
1979年 | 4篇 |
1978年 | 8篇 |
1977年 | 8篇 |
1976年 | 2篇 |
1975年 | 3篇 |
1973年 | 1篇 |
排序方式: 共有668条查询结果,搜索用时 15 毫秒
1.
2.
H A Roels R R Lauwerys J P Buchet A M Bernard P Lijnen G Van Houte 《British journal of industrial medicine》1990,47(5):331-337
A significant reduction of kallikrein activity in urine (assayed by its amidolytic activity) was found in 64 normotensive workers who had been exposed to cadmium for 11 years on average and whose cadmium concentrations in urine ranged from 2.2 to 33.1 micrograms/g creatinine. The mean (geometric) urinary kallikrein activity (in U/g creatinine) amounted to 0.52 (range 0.11-1.90) in the control group (n = 193) against 0.39 (range 0.10-1.03) in the cadmium group, and the prevalence of abnormally low activity levels (less than or equal to 0.20 U/g creatinine) amounted to 17.2% in the cadmium group against 5.2% in the control group. A reduction of aldosterone release (aldosterone in urine) associated with an increased natriuresis was also observed. This might constitute a compensatory mechanism maintaining blood pressure in the normal range. These biological effects of cadmium were not reversible after removal from exposure. This study indicates that cadmium can induce an irreversible toxic effect in the distal nephron. It also suggests that an excessive cadmium body burden alone may not be sufficient to induce hypertension, but in individuals whose blood pressure regulation may be impaired by other factors cadmium could stimulate the development of hypertension. This study also supports the recommendation to prevent hypertensive subjects from being exposed to cadmium. There was no indication that moderate exposure to mercury vapour (n = 53; mercury in urine, range 11-224 micrograms/g creatinine; average duration of exposure: six years) or to inorganic lead (n = 23; lead in blood, range 40-67 micrograms/100 ml; average duration of exposure: eight years) was associated with a reduction of kallikrein production by the kidney. 相似文献
3.
4.
J Staessen A Bernard J P Buchet F Claeys L Dekempeneer G Ducoffre R Fagard R Lauwerys P Lijnen H Roels 《IARC scientific publications》1992,(118):263-269
This paper summarizes the findings of the Cadmibel Study, a cross-sectional population study of the health effects of cadmium, but only with respect to the cardiovascular system and calcium metabolism. The study disproved the hypothesis that exposure to cadmium would lead to an increase in blood pressure and in the prevalence of hypertension and other cardiovascular diseases. On the other hand, there was a positive relationship between urinary cadmium (Cd-U) and both serum alkaline phosphatase activity and urinary excretion of calcium. The regression coefficients obtained after adjustment for significant co-variates indicated that, when Cd-U increased two-fold, serum alkaline phosphatase and urinary calcium rose by 4% and 0.25 mmol/24 h, respectively. These findings suggest that calcium metabolism is gradually affected as cadmium accumulates in the body. The morbidity associated with the latter phenomenon is still unknown, and requires further investigation, preferably in a longitudinal prospective population study, in which the incidence of morbid events would be monitored in relation to the cadmium body burden. 相似文献
5.
P Lijnen J R M'Buyamba-Kabangu R Fagard J Staessen W Lissens W Goossens A Amery 《Methods and findings in experimental and clinical pharmacology》1987,9(1):55-62
Erythrocyte concentrations and fluxes of sodium and potassium were investigated in normal white male subjects during dietary sodium restriction and repletion, each period lasting for 16 weeks. Intraerythrocyte sodium concentration decreased and red cell ouabain-sensitive 86Rubidium-uptake increased during dietary sodium restriction while no significant changes were observed in the total, furosemide-resistant and furosemide-sensitive sodium-efflux and the sodium, lithium-countertransport. The decrease in intraerythrocyte sodium concentration could have resulted from the observed increase in sodium, potassium-ATPase pump activity. The latter increase could have been secondary to the early decrease in a digitalis-like plasma inhibitor and the later increase could have been facilitated by the late rise in the intracellular adenosine triphosphate concentration, which is the energy supplier for this pump. During the subsequent first month of sodium repletion intraerythrocyte sodium concentration remained low. Red cell ouabain-sensitive 86Rubidium-uptake and adenosine triphosphate concentration remained elevated and returned to baseline only after 16 weeks. This long-term effect suggests either the involvement of a mechanism which can only be slowly reversible or a mechanism which is irreversible so that normalization takes place only when new red cells are released into the circulation. 相似文献
6.
7.
D Collen L Nelles F De Cock G Lemmens T Van Coetsem E Demarsin H R Lijnen 《Thrombosis research》1992,65(3):421-438
K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency in animal models of venous and arterial thrombosis, which consists of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA), was produced and conditioned for use in patients. Chinese hamster ovary cells were transfected with an expression plasmid containing the K1K2Pu cDNA, high producer cell lines were selected and scaled up in 800 cm2 roller bottles, and 350 ml conditioned cell culture medium was harvested 3 to 7 times at 2 to 5 day intervals. Batches of 21 +/- 4 liter (mean +/- SD, n = 28) containing 1.8 +/- 0.6 mg/l of K1K2Pu related antigen were purified by chromatography on Copper chelate-Sepharose and immunoadsorption on an insolubilized murine monoclonal antibody (MA-1C8). Yields were 8.6 +/- 3.4 mg K1K2Pu per batch with a specific activity of 83,000 +/- 44,000 IU/mg. The final material, obtained at a concentration of approximately 0.7 mg/ml, was dialyzed against 0.3 M NaCl, 0.02 M Tris-HCl buffer, pH 7.5, containing 0.01% Tween 80 and 10 KIU/ml aprotinin. It was homogeneous on SDS-PAGE, contained 6.5 +/- 6.9 percent two chain material and the contamination with murine monoclonal antibody was less than 0.1 percent. After filtration of pools of 3 to 5 selected batches on 0.22 microns Millipore filters the material was sterile and virus free by routine screening; it was obtained at a concentration of approximately 0.5 mg/ml with a specific activity of 110,000 +/- 16,000 IU/mg (mean +/- SD, n = 3) and an endotoxin content of 0.5 to 7 units/mg. Bolus injection at a dose of 1 mg/kg in mice did not produce weight loss within 8 days. Thus, this material appears to be suitable for the investigation on a pilot scale of the pharmacokinetic and thrombolytic properties of K1K2Pu in patients with thromboembolic disease. 相似文献
8.
E. Pujade-Lauraine H. Lu S. Mirshahi J. Soria C. Soria A. Bernadou E. K. O. Kruithof H. R. Lijnen P. Burtin 《International journal of cancer. Journal international du cancer》1993,55(1):27-31
We studied the plasminogen activation system in tumor tissue by measuring the antigen level of the 2 plasminogen activators, tissue-type (t-PA) and urokinase-type (U-PA) and their inhibitors, plasminogen-activator inhibitors type-1 (PAI-1) and type-2 (PAI-2) in the tissue extracts of 43 human benign and malignant ovarian tumors. U-PA levels were significantly higher in malignant than in benign tumors. In addition, U-PA antigen levels were higher in the metastatic tissue of advanced disease (FIGO stage III) than in the primary localized tumor (FIGO stage I/II). Also PAI-1 concentrations tended to be higher in malignant than in benign tumors, but this difference was not statistically significant. In contrast, t-PA levels were lower in metastatic than in non-metastatic tumors, whereas PAI-2 levels were unrelated to the stage of ovarian malignancy. These results were integrated in a plasminogen-activation-dependent malignancy index (U-PA × PAI-1/t-PA). This index distinguished the different groups of benign ovarian tumors, localized and metastatic ovarian carcinomas better than U-PA levels. It could be useful as a prognostic indicator in ovarian cancer © 1993 Wiley-Liss, Inc. 相似文献
9.
10.
Promoting clinically effective practice: general practitioners' awareness of sources of research evidence 总被引:3,自引:1,他引:2
Prescott K; Lloyd M; Douglas HR; Haines A; Humphrey C; Rosenthal J; Watt I 《Family practice》1997,14(4):320-323
BACKGROUND: Practitioners are being encouraged to base their clinical
practice on research evidence. In order to do this, they must be aware of
and use the sources of evidence. METHODS: A questionnaire survey was
undertaken to establish GPs' awareness of research evidence in their
clinical practice and, in fundholding practices, its influence on
purchasing plans. Questionnaires were sent to 360 lead fundholders in North
Thames Region and 440 of a random sample of the remaining general
practitioners in the region for comparison. RESULTS: Questionnaires were
returned by 62% of lead fundholders and 63% of GPs in the random sample.
There was limited use of the electronic sources of clinical effectiveness.
There was greater reported awareness of published sources of research
evidence and fundholding GPs were significantly more likely to have
referred to publications summarizing research evidence. CONCLUSIONS: GPs
seem to make more use of published clinical effectiveness sources than the
electronic databases. Consequently, they need educational and technical
support if they are to make full use of the available sources of research
evidence available in other media.
相似文献